GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (STU:5HU) » Definitions » Quick Ratio

Hemogenyx Pharmaceuticals (STU:5HU) Quick Ratio : 3.33 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Hemogenyx Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 3.33.

Hemogenyx Pharmaceuticals has a quick ratio of 3.33. It generally indicates good short-term financial strength.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's Quick Ratio or its related term are showing as below:

STU:5HU' s Quick Ratio Range Over the Past 10 Years
Min: 1.08   Med: 4   Max: 20.22
Current: 3.33

During the past 9 years, Hemogenyx Pharmaceuticals's highest Quick Ratio was 20.22. The lowest was 1.08. And the median was 4.00.

STU:5HU's Quick Ratio is ranked worse than
51.71% of 1551 companies
in the Biotechnology industry
Industry Median: 3.53 vs STU:5HU: 3.33

Hemogenyx Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Quick Ratio Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Feb15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 3.04 1.08 20.25 3.47 3.33

Hemogenyx Pharmaceuticals Semi-Annual Data
Feb15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.25 6.72 3.47 4.07 3.33

Competitive Comparison of Hemogenyx Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemogenyx Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Quick Ratio falls into.



Hemogenyx Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Hemogenyx Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2.519-0)/0.757
=3.33

Hemogenyx Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2.519-0)/0.757
=3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hemogenyx Pharmaceuticals  (STU:5HU) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Hemogenyx Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemogenyx Pharmaceuticals (STU:5HU) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (STU:5HU) Headlines

No Headlines